In a nutshell This study examined whether newer therapies for non-Hodgkin lymphoma (NHL) were associated with higher odds of negative side effects in older patients. The study concluded that NHL patients over age 65 experienced more serious side effects than younger patients, and these side effects were associated with worse outcomes. Some background...
Read MoreCurrent disease status-Recurrent lymphoma Posts on Medivizor
Does high-dose GBM chemotherapy lead to better post-stem cell transplant outcomes compared to BEAM in refractory or relapsed Hodgkin’s lymphoma patients?
In a nutshell This study investigated the outcomes of primary refractory or relapsed Hodgkin’s lymphoma (HL) patients who received GBM (gemcitabine, busulfan, melphalan) or BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). This study concluded that GBM improved patient outcomes...
Read MoreHow effective and safe is ibrutinib compared to temsirolimus for relapsed or persistent mantle cell lymphoma?
In a nutshell This study compared the effectiveness and safety of ibrutinib (Imbruvica) versus temsirolimus (Torisel) in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib significantly improved survival outcomes compared to temsirolimus for these patients. Some background...
Read MoreWhat are the outcomes for lymphoma patients who received TECAM chemotherapy before a stem cell transplant?
In a nutshell This study analyzed data from patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) who received TECAM (etoposide, thiotepa, cytarabine, cyclophosphamide, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). The authors concluded that TECAM is an effective pre-autoSCT regimen for...
Read MoreDoes brentuximab vedotin improve stem cell transplant outcomes for classical Hodgkin’s lymphoma patients?
In a nutshell This study investigated the outcomes of classical Hodgkin’s lymphoma (cHL) patients who did or did not receive brentuximab vedotin (Adcetris) before allogeneic stem cell transplantation. This study concluded that pre-transplant brentuximab vedotin treatment does not lead to better post-transplant outcomes. Some background...
Read MoreLow-dose radiotherapy for low-grade lymphoma: What are the outcomes?
In a nutshell This study investigated the effectiveness, side effects, and relapse patterns of patients with low-grade (indolent; painless) follicular lymphoma (FL) or marginal zone lymphoma (MZL) after low-dose radiotherapy (LDRT). This study concluded that LDRT is an effective treatment in patients with low-grade disease and a low tumor burden. Some...
Read MoreEffectiveness of autologous stem cell transplantation in elderly patients with lymphoma
In a nutshell This study looked at the effectiveness of treating elderly lymphoma patients with autologous stem cell transplantation. The study concluded that autologous stem cell transplantation should be considered on an individual basis, and age should not automatically disqualify elderly patients. Some background Patients with lymphoma...
Read MoreWhat are the long-term outcomes after plerixafor and G-CSF before stem cell transplantation?
In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read MoreTiming of allogenic stem cell transplantation in patients with relapsed follicular lymphoma
In a nutshell This study looked at the outcomes of patients with relapsed follicular lymphoma who were treated with allogeneic stem cell transplantation. The authors concluded that allogeneic stem cell transplantation is an effective treatment, and is most effective when treating earlier phases of the disease. Some background Follicular...
Read MoreWhat are the real-world outcomes for ASCT-ineligible patients with refractory or relapsed HL who are given brentuximab vedotin?
In a nutshell This study determined the real-world outcomes for patients with relapsed or refractory Hodgkin’s lymphoma (rrHL) who were given brentuximab vedotin (Adcetris) due to ineligibility for autologous stem cell transplant (ASCT). The study concluded that brentuximab vedotin is feasible and effective in patients with rrHL who are...
Read MoreCombined haploidentical-cord stem cell transplantation in lymphoma and CLL – what are the outcomes?
In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...
Read MoreCombined haploidentical-cord stem cell transplantation in lymphoma and CLL – what are the outcomes?
In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...
Read More
